explore -WSS

explore

author：hotspot 2025-10-04 03:59:54 - browse：6

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Prime Medicine says its gene editing passes test in monkeys

WSS

Gene therapy’s promise and the high cost of hope

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

What to know about the judge who will handle the Trump case

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Prime Medicine says its gene editing passes test in monkeys

focus

explore

focus

Apple is now the first public company to be valued at $3 trillion

Judge sides with young activists in first

As demand for Covid shots wanes, Moderna seeks its next success

Illumina slashes 2023 revenue projections yet again

Psychedelics group wrestles with new pharma identity

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Trump demands the U.S. pay no more for drugs than other countries … again

Lung cancer screening guidelines updated for cigarette smokers

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare must police algorithms in Medicare Advantage, Dems say

hotspot

Idaho college killings prosecutors challenge defense's grand jury claims

Be careful with at

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Live blog: Hearing on CRISPR

Infant mortality in U.S. rose last year for first time in decades: CDC

Infant mortality in U.S. rose last year for first time in decades: CDC

hotspot

hotspot

entertainment

explore